Diagnosis, treatment, prognostic factors and long-term outcome in papillary thyroid carcinoma

Minerva Endocrinologica

Volumn 33, Issue 4, 2008, Pages 359-379

  Pelizzo, M R ^a   Merante Boschin, I ^a   Toniato, A ^a   Pagetta, C ^a   Casal Ide, E ^a   Mian, C ^a   Rubello, D ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b S Maria Misericordia Hospital   (Italy)

Author keywords

Carcinoma, papillary; Prognosis; Thyroid neoplasms; Treatment outcome

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN RET; RAF PROTEIN; RAS PROTEIN; THYMIDINE; VALINE; RADIOACTIVE IODINE;

ADENOMATOUS POLYP; APOPTOSIS; AUTOPHOSPHORYLATION; CANCER INCIDENCE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME 10Q; CHROMOSOME 7; COWDEN SYNDROME; FAMILY HISTORY; GLIA CELL; GOITER; HISTOPATHOLOGY; IODINE DEFICIENCY; LYMPHOMA; MORPHOGENESIS; PERIPHERAL NERVE; PEUTZ JEGHERS SYNDROME; PROGNOSIS; RADIATION EXPOSURE; REVIEW; SCINTIGRAPHY; SWEDEN; THYROID CARCINOMA; TINEA CAPITIS; WERNER SYNDROME; CANCER STAGING; HUMAN; LYMPHADENECTOMY; MULTIMODALITY CANCER THERAPY; NEEDLE BIOPSY; PAPILLARY CARCINOMA; PATHOLOGY; RISK FACTOR; THYROID TUMOR; THYROIDECTOMY; TREATMENT OUTCOME;

BIOPSY, FINE-NEEDLE; CARCINOMA, PAPILLARY; COMBINED MODALITY THERAPY; HUMANS; IODINE RADIOISOTOPES; LYMPH NODE EXCISION; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 60849116175     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (122)

1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A national cancer Data Base report on 53.856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer 1998;83:2638-48.
2. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15.698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 1997;79:564-73.
3. Strate SM, Lee EL, Childers JH. Occult papillary carcinoma of the thyroid with distant metastases. Cancer 1984;54:1093-100.
4. Pelizzo MR, Boschin IM, Toniato A, Piotto A, Bernante P, Pagetta C et al. Papillary thyroid microcarcinoma (PTMC): prognostic factors, management and outcome in 403 patients. Eur J Surg Oncol 2006;32:1144-8.
5. Shah JP, Loree TR, Dhaker D, Strong EW, Begg C, Vlamis V. Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg 1992;164:658-61.
6. Cady B, Sedgwick CE, Meissner WA, Wool MS, Salzman FA, Werber J. Risk factor analysis in differentiated thyroid cancer. Cancer 1979;43:810-20.
7. Gosnell JE, Clark OH. Surgical approaches to thyroid tumors. Endocrinol Metab Clin North Am 2008;37:437-55.
8. Hedinger C, Williams ED, Sobin LH. The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer 1989;63:908-11.
9. Pelizzo MR, Toniato A, Grigoletto R. Surgical treatment of papillary thyroid carcinoma: uni- and multivariate analysis of prognostic factors (TNM staging system included). J Exp Clin Cancer Res 1997;16:261-5. (Pubitemid 27454934)
10. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297-306.
11. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164-7.
12. Haselkorn T, Bernstein L, Preston-Martin S, Cozen W, Mack WJ. Descriptive epidemiology of thyroid cancer in Los Angeles County, 1972-1995. Cancer Causes Control 2000;11:163-70.
13. Liu S, Semenciw R, Ugnat AM, Mao Y. Increasing thyroid cancer incidence in Canada, 1970-1996: time trends and age-period-cohort effects. Br J Cancer 2001;85:1335-9.
14. Hodgson NC, Button J, Solorzano CC. Thyroid cancer: is the incidence still increasing? Ann Surg Oncol 2004;11:1093-7.
15. Reynolds RM, Weir J, Stockton DL, Brewster DH, Sandeep TC, Strachan MW. Changing trends in incidence and mortality of thyroid cancer in Scotland. Clin Endocrinol (Oxf) 2005;62:156-62.
16. Colonna M, Grosclaude P, Remontet L, Schvartz C, Mace-Lesech J, Velten M et al. Incidence of thyroid cancer in adults recorded by French cancer registries (1978-1997). Eur J Cancer 2002;38:1762-8.
17. Leenhardt L, Bernier MO, Boin-Pineau MH, Conte Devolx B, Marechaud R, Niccoli-Sire P et al. Advances in diagnostic practices affect thyroid cancer incidence in France. Eur J Endocrinol 2004;150:133-9.
18. Pacini F, Vorontsova T, Demidchik EP, Molinaro E, Agate L, Romei C et al. Post-Chernobyl thyroid carcinoma in Belarus children and adolescents: comparison with naturally occurring thyroid carcinoma in Italy and France. J Clin Endocrinol Metab 1997;82:3563-9.
19. Franceschi S, Boyle P, Maisonneuve P, La Vecchia C, Burt AD, Kerr DJ et al. The epidemiology of thyroid carcinoma. Crit Rev Oncog 1993;4:25-52.
20. Sampson RJ, Key CR, Buncher CR, Iijima S. Thyroid carcinoma in Hiroshima and Nagasaki. I. Prevalence of thyroid carcinoma at autopsy. JAMA 1969;209:65-70.
21. Franssila KO, Harach HR. Occult papillary carcinoma of the thyroid in children and young adults. A systemic autopsy study in Finland. Cancer 1986;58:715-9.
22. Yamamoto Y, Maeda T, Izumi K, Otzuka H. Occult papillary carcinoma of the thyroid. A study of 408 autopsy cases. Cancer 1990;65:1173-9.
23. Kent WD, Hall SF, Isolato PA, Houlden RL, George RL, Groome PA. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ 2007 Nov 20; 177:1357-61.
24. Saad AG, Kumar S, Ron E, Lubin JH, Stanek J, Bove KE et al. Proliferative activity of human thyroid cells in various age groups and its correlation with the risk of thyroid cancer after radiation exposure. J Clin Endocrinol Metab 2006;91:2672-7.
25. Sont WN, Zielinski JM, Ashmore JP, Jiang H, Krewski D, Fair ME et al. First analysis of cancer incidence and occupational radiation exposure based on the National Dose Registry of Canada. Am J Epidemiol 2001;153:309-18.
26. Shore RE. Issues and epidemiological evidence regarding radiation-induced thyroid cancer. Radiat Res 1992;131:98-111.
27. Thompson DE, Mabuchi K, Ron E, Soda M, Tokunaga M, Ochikubo S et al. Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958-1987. Radiat Res. 1994;137:S17-67. Erratum in: Radiat Res 1994;139:129.
28. Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 1995;141:259-77.
29. Sigurdson AJ, Ronckers CM, Mertens AC, Stovall M, Smith SA, Liu Y et al. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. Lancet 2005;365:2014-23.
30. Williams D. Cancer after nuclear fallout: lessons from the Chernobyl accident. Nat Rev Cancer 2002;2:543-9. (Pubitemid 37328936)
31. Galanti MR, Hansson L, Bergstrom R, Wolk A, Hjartaker A, Lund E et al. Diet and the risk of papillary and follicular thyroid carcinoma: a population-based case-control study in Sweden and Norway. Cancer Causes Control 1997;8:205-14.
32. Malchoff CD, Malchoff DM. The genetics of hereditary nonmedullary thyroid carcinoma. J Clin Endocrinol Metab 2002;87:2455-9.
33. Loh KC. Familial nonmedullary thyroid carcinoma: a meta-review of case series. Thyroid 1997;7:107-13.
34. Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 2008;8:83-95.
35. Delys L, Detours V, Franc B, Thomas G, Bogdanova T, Tronko M et al. Gene expression and the biological phenotype of papillary thyroid carcinomas. Oncogene. 2007 Dec 13;26(57):7894-903.
36. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007;28:742-62.
37. th edition. New York: Springer; 2002. p. 89-98.
38. Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002;26:879-85.
39. Van Nguyen K, Dilawari RA. Predictive value of AMES scoring system in selection of extent of surgery in well differentiated carcinoma of thyroid. Am Surg 1995;61:151-5.
40. Pasieka JL, Zedenius J, Auer G, Grimelius L, Hoog A, Lundell G et al. Addition of nuclear DNA content to the AMES risk-group classification for papillary thyroid cancer. Surgery 1992;112:1154-9; discussion 1159-60.
41. Dean DS, Hay ID. Prognostic indicators in differentiated thyroid carcinoma. Cancer Control 2000;7:229-39.
42. Tennvall J, Biorklund A, Moller T, Ranstam J, Akerman M. Is the EORTC prognostic index of thyroid cancer valid in differentiated thyroid carcinoma? Retrospective multivariate analysis of differentiated thyroid carcinoma with long follow-up. Cancer 1986;57:1405-14. (Pubitemid 16136764)
43. Pelizzo MR, Boschin IM, Toniato A, Piotto A, Pagetta C, Gross MD et al. Papillary thyroid carcinoma: 35-year outcome and prognostic factors in 1858 patients. Clin Nucl Med 2007;32:440-4.
44. Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman HG et al. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology 2005;237:794-800.
45. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993;328:553-9.
46. Pacini F, Burroni L, Ciuoli C, Di Cairano G, Guarino E. Management of thyroid nodules: a clinicopathological, evidence-based approach. Eur J Nucl Med Mol Imaging 2004;31:1443-9.
47. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W; European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787-803. Erratum in: Eur J Endocrinol 2006;155:385.
48. Marqusee E, Benson CB, Frates MC, Doubilet PM, Larsen PR, Cibas ES et al. Usefulness of ultrasonography in the management of nodular thyroid disease. Ann Intern Med 2000;133:696-700.
49. Cap J, Riska A, Rehorkova P, Hovorkova E, Kerekes Z, Pohnetalova D. Sensitivity and specificity of the fine needle aspiration biopsy of the thyroid: clinical point of view. Clin Endocrinol (Oxf) 1999;51:509-15.
50. Braga M, Cavalcanti TC, Collaco LM, Graf H. Efficacy of ultrasound-guided fine-needle aspiration biopsy in the diagnosis of complex thyroid nodules. J Clin Endocrinol Metab 2001;86:4089-91.
51. Mulchahy MM, Cohen JI, Anderson PE, Ditamasso J, Schmidt W. Relative accuracy of fine-needle aspiration and frozen section in the diagnosis of well-differentiated thyroid cancer. Laryngoscope 1998;108:494-6.
52. Goldstein RE, Netterville JL, Burkey B, Johnson JE. Implications of follicular neoplasms, atypia, and lesions suspicious for malignancy diagnosed by fine-needle aspiration of thyroid nodules. Ann Surg 2002;235:656-62; discussion 662-4.
53. Toniato A, Boschin IM, Piotto A, Pelizzo MR, Guolo AM, Foletto M et al. Complications in thyroid surgery for carcinoma: one institution's surgical experience. World J Surg 2008;32:572-5.
54. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987;102:1088-95
55. Mazzaferri EL, Jhiang SM. Long term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28
56. Pelizzo MR, Boschin IM, Toniato A, Pagetta C, Piotto A, Bernante P et al. Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC): a monoinstiturional 12-year experience. Nucl Med Commun 2004;25:547-52
57. Vickery AL Jr, Wang CA, Walker AM. Treatment of intrathyroidal papillary carcinoma of the thyroid. Cancer 1987;60:2587-95
58. Hay ID, Grant CS, Van Heerden JA, Goellner JR, Ebersold JR, Bergstralh EJ. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-years period. Surgery 1992;112:1139-46; discussion 1146-7
59. Strate SM, Lee EL, Childers JH. Occut papillary carcinoma of the thyroid with distant metastases. Cancer 1984;54:1093-100
60. Baudin E, Travagli JP, Ropers J, Mancusi F, Bruno-Bossio G, Caillon B et al. Microcarcinoma of the thyroid gland. The Gustave-Roussy Institute experience. Cancer 1998;83:553-9.
61. Pelizzo MR, Merante Boschin I, Toniato A, Piotto A, Bernante P, Pagetta C et al. Sentinel node mapping and biopsy in thyroid cancer: a surgical perspective. Biomed Pharmacother 2006;60:405-8.
62. Shaha AP. Management of the neck in thyroid cancer. Otorhinolaryngol Clin North Am 1998;31:823-31.
63. Mirallie E, Visset J, Sagan C, Hamy A, Le bodic MF, Paineau J. localization of cervical node metastasis of papillary thyroid carcinoma. World J Surg 1999;23:970-4.
64. Ozaki O, Hirai K, Maruyama S, Sageshima M, Mori T. Experimental and clinical studies on the thyroid chromo-lymphography. Part II:clinical study. Jpn J Surg 1982;83:53-9.
65. Frankenthaler RA, Sellin RV, Cangir A, Goepfert H. Lymph node metastasis from papillary-follicular thyroid carcinoma in young patients. Am J Surg 1990;160:341-3.
66. Noguchi M, Kinami S, Taniya T, Miyazaki I. Bilateral cervical lymph node metastases in well-differentiated thyroid cancer. Arch Surg 1990;125:804-6. (Pubitemid 20182165)
67. Mirallie E, Visset J, Sagan C, Hamy A, Le Bodic MF, Paineau J. Localization of cervical node metastasis of papillary thyroid carcinoma. World J Surg 1999;23:970-3; discussion 973-4.
68. Noguchi M, Kinami S, Kinoshita K, Kitagawa H, Thomas M, Miyazaki I et al. Risk of bilateral cervical lymph node metastases in papillary thyroid cancer. J Surg Oncol 1993;52:155-9.
69. Ohshima A, Yamashita H, Noguchi S, Uchino S, Watanabe S, Toda M et al. Indications for bilateral modified radical neck dissection in patients with papillary carcinoma of the thyroid. Arch Surg 2000;135:1194-8; discussion 1199.
70. Yamashita H, Noguchi S, Murakami N, Kawamoto H, Watanabe S. Extracapsular invasion of lymph node metastasis is an indicator of distant metastasis and poor prognosis in patients with thyroid papillary carcinoma. Cancer 1997;80:2268-72.
71. Noguchi S, Noguchi A, Murakami N. Papillary carcinoma of the thyroid. II. Value of prophylactic lymph node excision. Cancer 1970;26:1061-4.
72. Hamming JF, van de Velde CJ, Goslings BM, Fleuren GJ, Hermans J, Delemarre JF et al. Peroperative diagnosis and treatment of metastases to the regional lymph nodes in papillary carcinoma of the thyroid gland. Surg Gynecol Obstet 1989;169:107-14. Review.
73. Scheumann GF, Gimm O, Wegener G, Huneshagen H, Dralle H. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 1994;18:559-67; discussion 567-8.
74. McHenry CR, Rosen IB, Walfish PG. Prospective management of nodal metastases in differentiated thyroid cancer. Am J Surg 1991;162:353-6.
75. Coburn MC, Wanebo HJ. Prognostic factors and management considerations in patients with cervical metastases of thyroid cancer. Am J Surg 1992;164:671-6.
76. Grebe SK, Hay ID. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am 1996;5:43-63. (Pubitemid 26047382)
77. Ballantyne AJ. Neck dissection for thyroid cancer. Semin Surg Oncol 1991;7:100-6.
78. Miccoli P, Berti P, Frustaci GL, Ambrosini CE, Materazzi G. Video-assisted thyroidectomy: indications and results. Langenbecks Arch Surg 2006;391:68-71.
79. Henry JF, Audiffret J, Denizot A, Plan M. The nonrecurrent inferior laryngeal nerve: review of 33 cases, including two on the left side. Surgery 1988;104:977-84. (Pubitemid 19011975)
80. Toniato A, Boschin IM. Anatomic configurations of the recurrent laryngeal nerve and inferior thyroid artery. Surgery 2006;140:482-3.
81. Coady M, Adler F, Davila J, Gahtan V. Non recurrent laryngeal nerve during carotid artery surgery: case report and literature review. J Vasc Surg 2000;32:192-6.
82. Wheeler MH. Thyroid surgery and recurrent laryngeal nerve. Br J Surg 1999;86:291-2.
83. Blondeau P, Neouze GL, Rene L. The inferior non recurrent laryngeal nerve; hazards of thyroid surgery (7 cases). Ann Chir 1977;31:917-23.
84. Proye CA, Carnaille BM, Goropoulos A. Non recurrent and recurrent inferior laryngeal nerve : a surgical pitfall in cervical exploration. Am J Sung 1991;162:495-6.
85. Bayford D. An account of a singular case of obstructed deglutition. Mem Med Soc London 1789;2:271-2.
86. Stedman GW. A singular distribution of the nerves and arteries of the neck and the top of the thorax. Edinb Med Surg J 1823;19:564-5.
87. Toniato A, Mazzarotto R, Piotto A, Bernante P, Pagetta C, Pelizzo MR. Identification of the non recurrent laryngeal nerve during thyroid surgery: 20-year experience. World J Surg 2004;28:659-61.
88. Devèze A, Sebag F, Hubbard J, Jaunay M, Maweja S, Henry JF. Identification of patients with a non recurrent inferior laryngeal nerve by duplex ultrasound of the brachiocephalic artery. Surg Radiol Anat 2003;25:263-9.
89. Makay O, Icoz G, Yilmaz M, Akyildiz, Yetkin E. The recurrent laryngeal nerve and the inferior thyroid artery-anatomical variations during surgery. Langenbecks Arch Surg 2008 (Epub ahead of print).
90. Toniato A, Boschin IM. The Zuckerkandl tubercle. Am J Surg 2008;195:277.
91. Pelizzo MR, Toniato A, Gemo G. Zuckerkandl's tuberculum:an arrow pointing to the recurrent laryngeal nerve (constant anatomical landmark). J Am Coll Surg 1998;187:333-6.
92. Toniato A, Boschin IM, Piotto A, Pelizzo MR, Guolo A, Foletto M et al. Complications in thyroid surgery for carcinoma: one institution's surgical experience. World J Surg 2008;32:572-5.
93. Henry JF, Gramatica L, Denizot A, Kvachenyuk A, Puccini M, Defechereux T. Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma. Langenbecks Arch Surg 1998;383:167-9. (Pubitemid 28442533)
94. Bergamaschi R, Becouarn G, Ronceray J, Arnaud JP. Morbidity of thyroid surgery. Am J Surg 1998;176:71-5.
95. Evans WE, Mendelowitz DS, Liapis C, wolfe V, Florence CL. Motor speech deficit following carotid endarterectomy. Ann Surg 1982;196:461-4.
96. Rosato L, Avenia N, Bernante P, De Palma M, Gulino G, Nasi PG et al. Complications of thyroid surgery: analysis of a multicentric study on 14,934 patients operated on in Italy over 5 years. World J Surg 2004;28:271-6.
97. Myssiorek D. Recurrent laryngeal nerve paralysis: anatomy and etiology. Otolaryngol Clin North Am 2004;37:25-44.
98. Hermann M, Alk G, Roka R, Glaser K, Freissmuth M. Laryngeal recurrent nerve injury in surgery for benign thyroid diseases: effect of nerve dissection and impact of individual surgeon in more than 27,000 nerves at risk. Ann Surg 2002;235:261-8.
99. Serpell JW, Phan D. Safety of total thyroidectomy. ANZ J Surg 2007;77:15-9.
100. Cernea CR, Ferraz AR, Furlani J, Monteiro S, Nishio S, Hojaij FC et al. Identification of the external branch of the superior laryngeal nerve during thyroidectomy. Am J Surg 1992;164:634-9.
101. Kelley MJ, Kane TE, leggin BG. Spinal accessory nerve palsy: associated signs and symptoms. J Orthop Sports Phys Ther 2008;38:78-86.
102. Elefteriades J, Singh M, Tang P, Siegel MD, Kenney B, Pandey A et al. Unilateral diaphragm paralysis: etiology, impact, and natural history. J Cardiovasc Surg (Torino) 2008;49:289-95. (Pubitemid 351833252)
103. Ulivieri S. New classification of rating facial nerve dysfunction. G Chir 2008;29:45-6.
104. Policeni BA, smoker WR. Pathologic conditions of the lower cranial nerves IX, X, XI, and XII. Neuroimaging Clin N Am 2008;18:347-68.
105. Kong YX, Wright G, Pesudovs K, O'Day J, Wainer Z, Weisinger HS. Horner syndrome. Clin Exp Optom 2007;90:336-44.
106. Merante Boschin I, Meduri F, Toniato A, Pagetta C, Rubello D, Pelizzo MR. Cervical lymphorrea after nodal dissection: role of fasting based on clinical evidence. Minerva Chir 2006;61:57-62.
107. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447-63.
108. Kjellman P, Zedenius J, Lundell G, Backdahl M, Farnebo LO, Hamberger B et al. Predictors of outcome in patients with papillary thyroid carcinoma. Eur J Surg Oncol 2006;32:345-52.
109. Casara D, Rubello D, Saladini G, Masarotto G, Favero A, Girelli ME et al. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 1993;34:1626-31. (Pubitemid 23295368)
110. Hindié E, Zanotti-Fregonara P, Keller I, Duron F, Devaux JY, Calzada-Nocaudie M et al. Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcome. Endocr Relat Cancer 2007;14:799-807.
111. Borget I, Temy H, Chevalier J, Ricard M, Allyn M, Sclumberger M et al. Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen. Eur J Nucl Med Mol Imaging 2008;35:1457-63.
112. Zanotti-Fregonara P, Toubert ME, Taieb D, Ravasi L, Rubello D, Hindie E. Overview on the use of recombinant human thyrotropin in thyroid cancer of follicular cell origin. Minerva Endocrinol 2008;33:53-65.
113. Schlumberger M, Challeton C, de Vathaire F, Travagli JP, Gardet P, Lumbroso JD et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 1996;37:598-605. (Pubitemid 126618447)
114. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983;309:937-41.
115. Clark JR, Lai P, Hall F, Borglund A, Eski S, Freeman JL. Variables predicting distant metastases in thyroid cancer. Laryngoscope 2005;115:661-7.
116. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91:2892-9.
117. Pittas AG, Adler M, Fazzari M, Tickoo S, Rosai J, Larson SM et al. Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid 2000;10:261-8. (Pubitemid 30202413)
118. Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer 2005;12:49-64.
119. Pacini F, Cetani F, Miccoli P, Mancusi F, Ceccarelli C, Lippi F et al. Outcome of 309 patients with metastatic thyroid carcinoma treated with radioiodine. World J Surg 1994;18:600-4.
120. Grünwald F, Kälicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547-52.
121. Feine U, Lietzenmayer R, Hanke JP, Held J, Wöhrle H, Müller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996;37:1468-72. (Pubitemid 26321624)
122. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006;91:498-505.